ArticleFrontiers in toxicology2024
Editorial: European partnership on the assessment of risks from chemicals (PARC): focus on new approach methodologies (NAMs) in risk assessment.
Article in Frontiers in toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A new multi-residue method for PFAS analysis in wastewater for environmental and public health risk assessment.Analytical and bioanalytical chemistry · 2026Article
- Editorial: European partnership on the assessment of risks from chemicals (PARC): continued focus on new approach methodologies (NAMs) and data gap filling.Frontiers in toxicology · 2026Article
- From concept to regulation: OECD's role in the development of the DNTFrontiers in toxicology · 2026Review
- Scientific and Regulatory Perspectives on Chemical Risk Assessment of Pesticides in the European Union.Journal of xenobiotics · 2025Review
- Chemical risk analysis competence in the Nordics is at stake.Environmental science and pollution research international · 2025Article
- The digital evolution in toxicology: pioneering computational education for emerging challenges.BMC medical education · 2024Article
- Assessing Environmental Risks during the Drug Development Process for Parasitic Vector-Borne Diseases: A Critical Reflection.ACS infectious diseases · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.